Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telisotuzumab vedotin versus docetaxel in previously treated c-Met overexpressing EGFR wildtype non-squamous NSCLC
2023-505749-14-00Phase 3Authorised
- Sponsor
- AbbVie Inc.
- Start
- Nov 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 32
01
Overview
Phase 3, randomised, open-label trial in Non-small cell lung cancer (NS-NSCLC) comparing Telisotuzumab vedotin with Docetaxel (2 arms). Primary endpoints: Progression-free survival and Overall survival. Planned start Nov 2023; status: authorised.
02
Drugs
telisotuzumab vedotindocetaxel
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on 2023-505749-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505749-14-00.